Linguamatics' I2E natural language processing engine helps Sanofi match HLA alleles with multiple sclerosis and associated drug treatments.
The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
Berg will use its Interrogative Biology platform in order to assess potential biomarkers of seasonal influenza vaccination outcomes.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.
The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.
The study used a modified version of Myriad RBM's DiscoveryMAP immunoassay panel to measure levels of 237 proteins in blood samples from 8,401 patients.
The pharma firm joins Pfizer Canada and AstraZeneca in the National Access Project, which tests tumors for mutations to match patients with potential therapies.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.